Companies: 10,795·Total market cap: $144.5T
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

SCNINASDAQHealthcare● Active
$0.41
$-0.00(-1.14%)
Market Cap$536143
P/E Ratio
52W High$3.48
52W Low$0.367

Scinai Immunotherapeutics Ltd. (SCNI) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

SCNI · earnings · updated Jun 9, 2026

Latest Earnings

Q4 FY2025
EPS Actual
-$1.33
Revenue
$0.00B
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Dec 2, 2025
After Market Close
SCNI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.

EPS & Revenue vs. Estimates

Actual (Beat)
Actual (Miss)
Estimated

Earnings History

Q3 FY2026
Jul 7, 2026
EPS Actual
EPS Est.
EPS Surpr.
Revenue
Q2 FY2026
May 7, 2026
EPS Actual
EPS Est.
EPS Surpr.
Revenue
Q4 FY2025
Dec 2, 2025
EPS Actual
-$1.33
EPS Est.
EPS Surpr.
Revenue
$0.00B
Q3 FY2025
Sep 2, 2025
EPS Actual
-$3.57
EPS Est.
EPS Surpr.
Revenue
$0.00B
Q2 FY2025
May 30, 2025
EPS Actual
-$0.00
EPS Est.
EPS Surpr.
Revenue
$0.00B
Q2 FY2025
May 7, 2025
EPS Actual
-$10.40
EPS Est.
EPS Surpr.
Revenue
$0.00B
Q4 FY2024
Nov 22, 2024
EPS Actual
$8.40
EPS Est.
EPS Surpr.
Revenue
$0.00B
Q3 FY2024
Aug 15, 2024
EPS Actual
-$3.57
EPS Est.
EPS Surpr.
Revenue
$0.00B

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
PeriodLowConsensusHigh# Analysts
Q3 FY2028$-6.20$-6.20$-6.201
Q2 FY2028$-9.40$-9.40$-9.401
Q1 FY2028$-4.55$-4.55$-4.551
Q4 FY2027$-22.00$-22.00$-22.001
Q3 FY2027$-1.00$-1.00$-1.001
Q2 FY2027$-1.00$-1.00$-1.001
Revenue Estimates
PeriodLowConsensusHigh# Analysts
Q3 FY2028$0.0B$0.0B$0.0B1
Q2 FY2028$0.0B$0.0B$0.0B1
Q1 FY2028$0.0B$0.0B$0.0B1
Q4 FY2027$0.0B$0.0B$0.0B1
Q3 FY2027$0.0B$0.0B$0.0B1
Q2 FY2027$0.0B$0.0B$0.0B1

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.
Q4 FY2025+3.00%
Report Date
Dec 2, 2025
EPS Beat/Miss
Price Before
$1.00
Price After
$1.03
Q3 FY2025+0.65%
Report Date
Sep 2, 2025
EPS Beat/Miss
Price Before
$1.53
Price After
$1.54
Q2 FY2025+1.12%
Report Date
May 30, 2025
EPS Beat/Miss
Price Before
$2.69
Price After
$2.72
Q2 FY2025-0.36%
Report Date
May 7, 2025
EPS Beat/Miss
Price Before
$2.81
Price After
$2.80
Q4 FY2024+17.22%
Report Date
Nov 22, 2024
EPS Beat/Miss
Price Before
$3.02
Price After
$3.54
Q3 FY2024+1.89%
Report Date
Aug 15, 2024
EPS Beat/Miss
Price Before
$3.70
Price After
$3.77
Q3 FY2024+1.36%
Report Date
Jul 2, 2024
EPS Beat/Miss
Price Before
$2.94
Price After
$2.98
Q2 FY2024+0.00%
Report Date
May 15, 2024
EPS Beat/Miss
-38609.7%
Price Before
$4.40
Price After
$4.40
Avg Miss Reaction+0.00%
Beat Rate0 / 8 quarters
Largest Move+17.22% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Data source: Financial Modeling Prep (FMP)  |  Updated: Hourly  |  Surprise%: (Actual − Estimate) / |Estimate| × 100  |  Fiscal year: SCNI ends December

Scinai Immunotherapeutics Ltd. (SCNI) most recently reported earnings on December 2, 2025 for Q4 FY2025, posting EPS of $-1.33 (in line with the analyst consensus of —). The next SCNI earnings date is expected around September 1, 2026.

Each quarter, investors track SCNI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SCNI revenue tab →

Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SCNI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Frequently asked questions

SCNI earnings · 4 questions

Scinai Immunotherapeutics Ltd.'s next earnings report is expected around September 1, 2026. SCNI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SCNI historically reports after market close (AMC).

SCNI earnings datewhen is SCNI earningsSCNI next earnings datewhen does SCNI report earningsSCNI earnings calendar

Source: FMP · Scinai Immunotherapeutics Ltd. SEC filings · US GAAP · Scinai Immunotherapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026